Health Catalyst price target raised to $13 from $11 at Wells Fargo

Wells Fargo analyst Stan Berenshteyn raised the firm’s price target on Health Catalyst to $13 from $11 and keeps an Equal Weight rating on the shares. The firm said that Health Catalyst’s margin improvement is a positive development, though one-off cost efficiencies are unlikely to repeat and the expected mix shift toward Services may challenge incremental margin progression.